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CsA (cyclosporin A) is a hydrophobic undecapeptide that inhibits
CyPs (cyclophilins), a family of PPIases (peptidylprolyl cis–
trans isomerases). In some experimental models, CsA offers
partial protection against lethal cell injury brought about by
transient ischaemia; this is believed to reﬂect inhibition of CyP-
D, a mitochondrial isoform that facilitates formation of the
permeabilitytransitionporeinthemitochondrialinnermembrane.
To evaluate this further, we have targeted CsA to mitochondria so
that it becomes selective for CyP-D in cells. This was achieved by
conjugating the inhibitor to the lipophilic triphenylphosphonium
cation, enabling its accumulation in mitochondria due to the
inner membrane potential. In a cell-free system and in B50
neuroblastoma cells the novel reagent (but not CsA itself)
preferentially inhibited CyP-D over extramitochondrial CyP-
A. In hippocampal neurons, mitochondrial targeting markedly
enhanced the capacity of CsA to prevent cell necrosis brought
about by oxygen and glucose deprivation, but largely abolished
itscapacitytoinhibitglutamate-inducedcelldeath.Itisconcluded
that CyP-D has a major pathogenic role in ‘energy failure’, but
not in glutamate excitotoxicity, where cytoprotection primarily
reﬂects CsA interaction with extramitochondrial CyPs and
calcineurin. Moreover, the therapeutic potential of CsA against
ischaemia/reperfusion injuries not involving glutamate may be
improved by mitochondrial targeting.
Key words: cyclophilin (CyP), cyclosporin A (CsA), glutamate
toxicity, hippocampal neuron, ischaemia, necrosis.
INTRODUCTION
Ischaemic diseases, notably myocardial infarction and stroke,
are the leading cause of death and disability throughout the
world. In general, early restoration of blood ﬂow is essential to
restrict tissue damage. Paradoxically, however, as the duration of
ischaemia increases, cells become adversely sensitive to restored
blood supply, giving rise to additional damage on reperfusion
(reperfusion injury). Resolving the critical cellular changes that
underlie I/R (ischaemia/reperfusion) injury is a major goal in
developing effective therapies.
A mitochondrial pore model for I/R injury was derived from
two lines of evidence: ﬁrst, the commonality between factors
that induce formation of the PT (permeability transition) pore
and recognized cellular changes in I/R, principally cellular Ca
2+
overload, oxidative stress and depleted adenine nucleotides [1,2];
secondly, inhibition of both pore formation and cell necrosis
under pseudo-I/R by CsA (cyclosporin A) [3–5]. The non-
speciﬁc PT pore [6], with an estimated internal diameter of
2 nm [1], allows free ﬂow of low Mr solutes across the inner
membrane. Under these conditions, mitochondria carry out ATP
hydrolysis, rather than synthesis. Once ATP hydrolysis exceeds
the glycolytic capacity of the cell to maintain ATP, irreversible
injury leading to cell necrosis ensues. The PT pore model of
I/R injury is supported by whole organ and animal studies. In
particular, CsA can attenuate reperfusion-induced cell necrosis
in heart [7], brain [8] and other tissues. Use of 2-deoxyglucose
[9]andcalcein[10]revealsthatthemitochondrialinnermembrane
does become non-selectively permeable on reperfusion, and that
CsA can prevent the permeability changes. Genetic ablation of
CyP (cyclophilin)-D, a PT pore component and a target of CsA
(see below), markedly reduces infarct size in heart [11] and brain
[12] following transient ischaemia.
CyP-D is a PPIase (peptidylprolyl cis–trans isomerase) that
is located in the mitochondrial matrix [13] and is inhibited by
CsA. CyP-D overexpression promotes PT pore formation [14],
whereas CyP-D ablation attenuates it [15]. It is believed that,
under pathological conditions, CyP-D catalyses or stabilizes a
proline-dependent conformational switch in an inner membrane
protein to form the non-selective PT pore. Conceivably, the CyP-
D-sensitive protein is a transport protein that loses its selective
transport properties when exposed to high Ca
2+ concentrations
and oxidative stress. Reconstitution studies indicate that the
adenine nucleotide translocase can deform into a non-selective
pore under the inﬂuence of Ca
2+ and CyP-D [16,17], but
mitochondria from mice lacking the two translocase isoforms do
displayPTporeactivity,albeitwithmuchreducedCa
2+ sensitivity
[18], and additional (or possibly alternative) inner membrane
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proteins that can interact with CyP-D, e.g. the phosphate carrier
[19], have been proposed. Irrespective of the identity of the pore
protein itself, however, there is little doubt that CsA inhibits PT
pore formation by inhibiting CyP-D.
However, despite this evidence that CyP-D has a key role in I/R
injury, cytoprotection by CsA in experimental models is highly
variable (and frequently marginal) and, in recent pilot trials, CsA
yielded modest protection [20]. This suggests that CyP-D has a
restricted pathogenic function and/or that CsA sensitivity is not
a precise indicator of CyP-D involvement in cell death, possibly
due to interaction with other CyPs ; the cytosolic CyP-A and
the endoplasmic reticulum CyP-B also have known links to cell
viability (see the Discussion section).
In order to shed light on these issues, we have developed
a novel CsA derivative that is effectively CyP-D selective in
cells because it accumulates in the mitochondrial compartment.
Application of the mtCsA (mitochondrially targeted CsA) to
hippocampalneuronsindicatesthatCyP-Dhasamajorpathogenic
role in energy failure, but only a minor role in glutamate
excitotoxicity. Moreover, the cytoprotective capacity of CsA
against the adverse consequences of energy failure is markedly
improved by mitochondrial targeting.
EXPERIMENTAL
Preparation of recombinant CyP-D and CyP-A
Recombinant rat CyP-D was prepared and puriﬁed as described
previously [14]. For CyP-A, the coding sequence in rat was PCR-
ampliﬁedwiththeadditionofBamH1andEcoR1restrictionsites,
and cloned between the same sites of pGEX-4T-1 in Escherichia
coli DH5α cells. Transformed cells were grown for 5 h at
21◦C. The GST (glutathione transferase)–CyP-A fusion protein
was extracted, puriﬁed on a GSH–Sepharose column (Sigma–
Aldrich), and then cleaved with thrombin to release CyP-A. The
CyP-A was puriﬁed on a cation exchange column (Mono S®;
Amersham Pharmacia) and by a gel ﬁltration column (Superdex-
75; Amersham Pharmacia) to give a single band on SDS/PAGE.
Interactions of cyclosporins with CyPs and calcineurin
Dissociation constants for CyP–cyclosporin interactions were
measuredasinhibitorconstants,Ki.PPIaseassayswereconducted
at15◦Cin20 mMHepes,pH7.5,containing100 mMNaClusing
N-succinyl-alanyl-alanyl-prolyl-4-nitroanilide as the test peptide
as described previously [14]. The peptide contains a mixture of
cis-a n dtrans-alanine–proline isomers, of which only the trans-
conformerishydrolysedbychymotrypsinattheC-terminalamide
bond to release chromophore. Existing trans-isomer is cleaved
within the mixing time, hence further cleavage requires cis–
trans isomerization, which is measured. CyPs were preincubated
with cyclosporins for 5 min before addition of chymotrypsin and
60 μM peptide (containing approx. 35 μM cis-peptide) to start
the reaction. Cyclosporins inhibit by competing at the active site
with substrate [21]. Accordingly, kinetic data were analysed by
the Henderson equation for a tight-binding, competitive inhibitor













where Eo and Io are the total concentrations of enzyme and
inhibitor (cyclosporin) respectively, Ki is the enzyme inhibitor
dissociation constant, Km is the Michaelis constant and [S] is the
substrate concentration. P is the fractional inhibition, equal to
{1−(vi/vo)},w h e r evi and vo are the reaction velocities in the
presence and absence of inhibitor respectively. The Km value
for the cis-peptide used (980 μM; [21]) is much higher than its







• Ki + Eo
and plots of Io/P against 1/(1−P) are linear with slope equal to
Ki.
Interaction of CyP–cyclosporin complexes with calcineurin
[alsoknownasPPP3CA(proteinphosphatase3,catalyticsubunit,
α isoform)] was evaluated from inhibition of the phosphatase
activity of calcineurin as measured by the release of inorganic
phosphate from the RII phosphopeptide (Biomol International).
Experiments with isolated mitochondria
Mitochondriawereisolatedfromratliversasdescribedpreviously
[1]. All animal experimentation conformed to U.K. Home
Ofﬁce legislation. PT pore opening was monitored by the
associated swelling of the mitochondria [9] as measured by
the decrease in absorbance at 540 nm. Mitochondria (2 mg of
protein) were suspended in 3 ml of buffer (10 mM Hepes, pH 7.2,
containing 120 mM KCl, 2 mM KH2PO4, 3 mM succinate, 1 μM
rotenone and 5 μM EGTA) with the recombinant CyP-A and test
cyclosporins, and maintained under continuous stirring at 25◦C.
After 5 min, calcium chloride was slowly infused (at 10 μM/min)
to a ﬁnal concentration of 50 μM. Changes in preincubation time
with CsA or mtCsA from 5 min to 2 min or 10 min did not
change the degree of PT pore inhibition. In a parallel incubation,
mitochondria were sedimented at the time indicated and the CyP-
A activity of the supernatant determined (0.5 ml of supernatant
per ml of reaction volume).
Neuronal cultures and assays
B50 cells from a rat neuronal cell line and a clone stably
overexpressing CyP-D were cultured on coverslips in DMEM
(Dulbecco’s minimal essential medium) containing 10% (v/v)
FBS (fetal bovine serum) as described previously [14]. Uptake
of TMRE (tetramethylrhodamine ethyl ester) was measured
by incubating the cells at 25◦C in basic medium (24 mM
Hepes, pH 7.4, containing 140 mM NaCl, 4 mM KCl, 1 mM
MgSO4, 1 mM CaCl2,1 m MK H 2PO4 and 11 mM glucose)
containing 50 nM TMRE. Fluorescence images were obtained
at an excitation wavelength of 530 nm and emission wavelength
of >595 nm with an Olympus IX-70 ﬂuorescence microscope
with a ×60 oil objective, Micromax 1401E CCD (charge-
coupled-device) camera and Metamorph software (Molecular
Devices). For nitroprusside treatment, cells were incubated in
basic medium containing 100 μM sodium nitroprusside for
40 min and then returned to DMEM. After 5 h, cells were
extracted and the extracts were assayed for caspase-3 activity
using the ﬂuorescent derivative of the caspase-3/7 selective
substrate, Ac-DEVD (N-acetyl-Asp-Glu-Val-Asp-)-AFC (7-
amino-4-triﬂuoromethylcoumarin), as described previously [23].
For antisense suppression of CyP-A, cells were incubated with
1 μM phosphorothioate oligodeoxynucleotide (5
 -CATGGCT-
TCCACAATGCT) for 48 h [23].
Hippocampal neurons were prepared from 2–4-day-old
Sprague–Dawleyratsasmixedcultureswithglialcells.Dissected
hippocampi were incubated in HBSS (Hanks balanced salt
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Figure 1 Chemical synthesis of the CsA analogues, and their binding by CyPs
The reagents used in each step are: i) lithium diisopropylamide, trimethylsilyl chloride, 4-bromomethylbenzoate; ii) LiOH, methanol; iii) Fmoc-diaminohexane, PyBOP; iv) piperidine, DMF; and v)
5-(carboxypentyl)triphenylphosphoniumbromide,PyBOP.Compound(1) isCsA,compound(2) SMBz-CsA andcompound(4) mtCsA.Thelower tableshowsthedissociation constants[determined
as inhibitor constants (Ki) as described for Figure 2] for the binding of CsA and the CsA analogues to CyP-D and CyP-A.
solution) containing 0.1% trypsin for 5 min at 37◦C, and were
washed twice in HBSS. Hippocampi were then dissociated
in HBSS containing 1 mg/ml BSA, 5% (v/v) FBS and
8m M M g C l 2. Dissociated cells were sedimented, suspended
in NBA (Neurobasal A) medium (Gibco) supplemented with
0.5 mM glutamine, 2% (v/v) B27 supplement (Gibco) and
5% (v/v) FBS, seeded onto coverslips and incubated under
95% air/5% CO2 in the same medium with an antimitotics
mix (1 μM of each of 5-ﬂuor-2
 -deoxyuridine, uridine and 1-β-
D-arabinofuranosylcytosine). Medium without antimitotics was
introduced after 3 days.
For OGD (oxygen and glucose deprivation) experiments,
coverslips with hippocampal neurons were seated to form the
baseofasmall,cappedchambermountedonthemicroscopestage.
Thechambercontainedaninletandoutletforcontinuousgassing,
input and output tubes for changing the incubation medium, and a
heating element to maintain the temperature at 36◦C. Pseudo-
ischaemic conditions were imposed by omitting glucose and
displacing air with nitrogen in the experimental chamber. Cells
wereincubatedunder95%N2/5%CO2 withapregassedsolution
of 145 mM NaCl, 26 mM NaHCO3,5m MK C l ,1 . 8m MC a C l 2,
0.8 mMMgCl2,4μMethidiumhomodimer,2 μMHoechst33342
and the cyclosporins as indicated. After 30 min the gassing was
switchedto95%air/5%CO2 andthemediumreplacedwithNBA
medium containing 4 μM ethidium homodimer. Hippocampal
neurons were identiﬁed under brightﬁeld illumination and then
correlated with their respective nuclei (just above the focal plane
of glia nuclei) from the Hoechst ﬂuorescence. Necrosis was
quantiﬁed from the nuclear staining by ethidium homodimer. For
treatment with glutamate, cultures were incubated under 95%
air/5% CO2 in a solution of Locke’s medium (5 mM Hepes,
150 mM NaCl, 5 mM KCl, 25 mM NaHCO3, 2.3 mM CaCl2
and 6 mM glucose) with the cyclosporins as indicated. After
10 min, 1 mM glutamate was added. After a further period, as
indicated,cellswerereturnedtoNBAmediumcontainingHoechst
33342 and ethidium homodimer, and necrosis was quantiﬁed
15 minlater.Furtherinhibitorsandantagonists[FK506, L-NAME
(N
G-nitro-L-arginine methyl ester), MK801, or NBQX (2,3-
dihydro-6-nitro-7-sulfamoylbenzoquinoxaline); Sigma–Aldrich]
were added as stated in the legend of Figure 8.
Statistical analyses were made using a one-way ANOVA
test with a post-test of Dunnett and results are presented as
means+ −S.E.M.
Synthesis of cyclosporin analogues
A scheme of the syntheses is given in Figure 1.
Synthesis of compound (2), SMBz [Sarcosine-3(4-methylbenzoate)]-CsA
To a stirred solution of CsA (1.00g, 0.83 mmol) in dry THF
(tetrahydrofuran, 25 ml) under nitrogen at 0◦C was added
dropwisefreshLDA(lithiumdiisopropylamide;4.6mmol,2.3 ml,
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2 M in THF). To the resultant deep-brown suspension was added,
dropwise, trimethylsilylchloride (0.83 mmol, 0.1 ml) to give a
clear brown solution. The mixture was stirred at 0◦C for 10 min.
Then further LDA (7.1 mmol, 3.5 ml, 2 M in THF) was added
dropwise and the reaction stirred for 30 min at 0◦C. A solution
of 4-bromomethylbenzoate (1.3 g, 5.8 mmol) in dry THF (10 ml)
was added dropwise to give a pale yellow solution which was
stirred for a further 1 h at room temperature (22◦C). The reaction
wasquenchedwithsaturatedNH4Cl(aq)(10ml)followedby2M
HCl and then diluted with DCM (dichloromethane) (20 ml). The
separated aqueous layer was extracted with DCM (2×20 ml).
The combined organic phases were washed with 2 M HCl (aq)
(2×20 ml), saturated NH4Cl (aq) (2×20 ml) and saturated NaCl
(2×20 ml) and then dried (MgSO4). The volatiles were removed
in vacuo to leave a dark brown oil residue. Puriﬁcation by ﬂash
chromatography eluting with 6% (v/v) methanol in DCM gave a
yellow solid residue (0.930 g) as a mixture of the unreacted CsA
and the alkylated ester product. This was used in the next reaction
without further puriﬁcation.
Saponiﬁcation was next performed. To a stirred solution of the
yellow solid residue (0.93 g) in THF/methanol (1:1, 20 ml) at
0◦C was added dropwise a solution of LiOH·H2O (500 mg) in
water (10 ml). The reaction was allowed to gradually warm-up to
room temperature over 18 h. Then DCM (20 ml) was added. The
resultant solution was acidiﬁed with 2 M HCl (aq) (pH 3). The
separated aqueous layer was extracted with DCM (3×30 ml).
The combined organic extracts were washed with saturated 2 M
HCl (aq) (2×30 ml) and saturated NaCl (2×30 ml) and then
dried (MgSO4). The volatiles were removed in vacuo to leave a
solid residue as a mixture of the acid [Figure 1, compound (2)]
andunreactedCsA.TheacidwasseparatedfromtheCsAbyﬂash
column chromatography through an amine column eluting with
a mixture of methanol/DCM/NH3 (aq) (1:8:1) to give the acid as
a salt. After stirring the salt in DCM (20 ml) and 2 M HCl (aq)
(20ml)for10min,extractionbyDCM(3×20ml),concentration,
and puriﬁcation by ﬂash column chromatography gave the title
compound, (2) (0.30 g, 0.24 mmol, 27%) as a yellow solid.
Fast atom bombardment MS in positive ionization mode:
calculated m/z C70H117N11O14 (M+Na) 1358.86787; found m/z
(M+Na) 1358.86447.
Synthesis of compound (3)
To a stirred solution of the acid compound (2) (109 mg,
0.08 mmol) in dry THF (3.0 ml) was added N-Fmoc (ﬂuoren-
9-ylmethoxycarbonyl)-1,6-diaminohexane hydrobromide (68.5
mg, 0.16 mmol), PyBOP (benzotriazol-1-yl-tris-pyrroli-
dinophosphonium hexaﬂuorophosphate; 84.5 mg, 0.16 mmol)
and triethylamine (0.25 mmol, 0.4 ml) under nitrogen at room
temperature and the resultant mixture was stirred for 24 h. Then
DCM (5 ml) followed by saturated NH4Cl (aq) (5 ml) were
added. The mixture was extracted with DCM (2×3m l )a n d
dried (MgSO4). The volatiles were removed in vacuo to leave
a brown oil residue. Puriﬁcation by chromatography gave the
Fmoc-protected derivative (100 mg) as a yellow solid. This was
used without further puriﬁcation.
Fmoc-deprotectionwasnextperformed.AsolutionoftheFmoc
compound (100 mg) was stirred in 20% piperidine in DMF
(dimethylformamide; 4 ml) under argon for 24 h. The volatiles
were removed al vacuo to leave a yellow oil. The oil was puriﬁed
by ﬂash column chromatography on silica gel eluting with 6%
methanol in DCM followed by methanol/DCM/NH3 (aq) (1:8:1)
to afford the title compound (3) (70 mg, 0.05 mmol, 85%)a sa
yellow solid.
ESI–MS (electrospray ionization MS) in positive ionization
mode: calculated m/z C76H131N13O13 (M+1) 1435.00, (M+2)
718; found m/z (M+1) 1435.53, (M+2) 718.76.
Synthesis of compound (4), mtCsA
To a stirred solution of the amine compound (3) (65 mg, 0.05
mmol) in dry THF (3 ml) under argon at room temperature
was added in one portion PyBOP (35.5 mg, 0.07 mmol),
5-(carboxypentyl)triphenylphosphonium bromide (32 mg, 0.07
mmol) and triethylamine (0.15 mmol, 0.05 ml) and the resultant
mixture stirred for 24 h at room temperature. The volatiles were
removed al vacuo to leave a yellow oil. The oil was puriﬁed by
ﬂash column chromatography on silica gel eluting with 6% (v/v)
methanol in DCM followed by methanol/DCM/NH3 (aq) (1:8:1)
to afford the title compound mtCsA, compound (4) (55 mg, 0.03
mmol, 70%) as a white solid.
ESI–MS in positive ionization mode: calculated m/z
C100H155N13O14P+ (M+1) 1793.8199; found m/z (M+1)
1794.8270, (M+2) 898.
RESULTS
Synthesis of CsA derivatives and their interactions with CyPs and
calcineurin
CsA is a lipophilic cyclic undecapeptide (Figure 1). The
highly conserved nature of the CsA-binding site in CyPs
offers little scope for CyP-D-selective cyclosporins (see the
Discussion). Therefore we investigated the possibility of
rendering CsA effectively CyP-D-selective in cells by targeting
it to mitochondria, where CyP-D is located. The strategy was
to conjugate CsA to the lipophilic TPP
+ (triphenylphosphonium)
cation so that the positively charged conjugate is accumulated
electrophoretically by mitochondria in response to the negative-
inside inner membrane potential. This principle has been widely
applied in targeting antioxidants to mitochondria [24]. Seebach
et al. [25] demonstrated that CsA may be speciﬁcally alkylated at
the sarcosine-3 position if several equivalents of a strong base are
used to generate a polyanion, and the same method was utilized
here,asshowninFigure1.Brieﬂy,CsA[Figure1;compound(1)]
was treated with LDA/trimethylsilyl chloride and then with LDA
to generate the sarcosine-3 anion. This was alkylated with 4-
bromomethylbenzoate and the crude product saponiﬁed with
lithium hydroxide to give the acid [Figure 1; compound (2)]. The
side chain was elongated by coupling with Fmoc-diaminohexane
and Fmoc cleavage yielded the amine [Figure 1; compound (3)].
This was coupled with 5-(carboxypentyl)triphenylphosphonium
bromide to give the target triphenylphosphonium salt, mtCsA
[Figure 1; compound (4)].
The effects of these modiﬁcations of CsA on interactions
with CyP-D and CyP-A were investigated by measuring PPIase
inhibition. Approx. 7 nM (total) CsA yielded 50% inhibition
of CyP-D (Figure 2A). However, this underestimated the true
CsA-binding afﬁnity as the assays had a similar concentration
of CyP-D, at 8 nM. Accordingly, inhibition was analysed using
the Henderson equation for a tight-binding inhibitor (see the
Experimental section), which gave an inhibitory (dissociation)
constantforCsAandCyP-Dof3 nM(Figure2A,inset).Additions
toposition-3impaired bindingslightly forSMBz-CsA(Figure1),
but strongly for mtCsA, where the binding afﬁnity to CyP-D was
approx. 30-fold lower than for CsA (Ki of 93 nM; Figure 2B).
The binding afﬁnities of CsA, SMBz-CsA and mtCsA to CyP-A
were similar to those with CyP-D (Figure 1).
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Figure 2 CyP-D inhibition by CsA and mtCsA
The PPIase activity of recombinant CyP-D was determined in the presence and absence of
the given concentrations of (A) CsA and (B) mtCsA. Each data point is the average of two
determinationsdifferingby<7%.Insetsshowresultswhenreplottedaccordingtothesimpliﬁed
Henderson equation as described in the Experimental section yielding values for Ki (slope).
In addition to inhibiting CyPs, CsA forms a complex with
CyP-A that, in turn, inhibits the Ca
2+/calmodulin-dependent
serine/threonine protein phosphatase, calcineurin [26], thereby
enlarging considerably CsA’s sphere of action [27]. It was
important therefore to establish how the position-3 modiﬁcation
affected the capacity of the complex to inhibit calcineurin.
To enable comparisons, the concentrations of CsA, SMBz-
CsA and mtCsA (at 0.9, 1 and 4 μM respectively) in the test
incubations were chosen to establish the same concentrations
(720 nM) of their respective complexes with CyP-A (calculated
using the Ki values of CyP-A with CsA, SMBz-CsA and
mtCsA; Figure 1). Figure 3 shows that, whereas CyP-A alone
produced a small (20%) activation of calcineurin, the CsA–
CyP-A complex inhibited calcineurin by approx. 70%.I n
contrast, the SMBz-CsA–CyP-A and mtCsA–CyP-A complexes
produced no inhibition. Conjugation to position-3 of the CsA ring
evidently prevents formation of the ternary CyP–cyclosporin–
calcineurin complex, which is known to require interactions
between calcineurin and positions 3–7 of the ring (see the
Discussion).
Evaluating the CyP-D selectivity of mtCsA in a mixed in vitro system
We ﬁrst investigated whether mtCsA would select for intramito-
chondrial CyP-D and the PT pore, rather than extramitochondrial
CyPs, using a test system comprising isolated mitochondria and
externally added, recombinant, CyP-A. PT pore opening was
induced by addition of a high concentration of Ca
2+,a n dw a s
monitored by the resultant mitochondrial swelling, as the inner
membrane became freely permeable to low-Mr solutes. As Ca
2+
Figure 3 Complexes of CyP-A with SMBz-CsA and mtCsA do not inhibit
calcineurin
The phosphatase activity of calcineurin was measured in the presence and absence of CyP-A,
CsA, SMBz-CsA and mtCsA at concentrations to give 720nM complexes (see the Experimental
section).
inﬂux into mitochondria is electrophoretic, the inner membrane
potential,  ϕM, becomes dissipated during rapid Ca
2+ uptake
{and then restored when uptake is complete (e.g. see [14])}.
As dissipation of  ϕM would compromise accumulation of the






and CsA to block PT pore opening; results not shown). CsA and
its derivatives inhibited pore opening (Figures 4A, 4C and 4E).
Estimation of the degrees of inhibition, assessed by the decreases
in absorbance (at the time marked by the broken lines in Figure
4) indicated that approx. 0.1 μM CsA and 0.4 μMm t C s Ag a v e
50% inhibition of PT pore opening (Figures 4B and 4D, closed
symbols). In the same system, CsA inhibited extramitochondrial
CyP-A with a concentration proﬁle similar to that of the PT pore
(Figure 4B); this was expected given that CyP-D and CyP-A have
similarbindingafﬁnitiesforCsA(Figure1)and,beinguncharged,
CsA should equilibrate to the same free concentrations on either
side of the inner membrane. In contrast, mtCsA inhibited PT pore
formation considerably better than it inhibited CyP-A (Figure
4D), even though it binds to CyP-A and CyP-D with similar
afﬁnities (Figure 1). This indicates that mtCsA was accumulated
inthemitochondrialmatrix,whereCyP-Dislocated,inpreference




Evaluating the CyP-D selectivity of mtCsA in intact cells
Selectivity of mtCsA for CyP-D in intact cells was investigated
using rat B50 neuroblastoma cells and a clone in which
CyP-D is overexpressed by approx. 10-fold (CyP-D+). CyP-
D overexpression did not affect CyP-A (Figure 5F). As shown
previously [14], CyP-D+ cells maintain a relatively low  ϕM,
indicative of transient PT pore opening. As the lowering of  ϕM
is caused by excessive CyP-D, restoration of  ϕM to wild-type
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Figure 4 mtCsA preferentially inhibits intramitochondrial CyP-D, rather than extramitochondrial CyP-A, in a mixed in vitro system
(A, C and E) Isolated liver mitochondria were incubated with added recombinant CyP-A. After preincubation with CsA, mtCsA or SMBz-CsA, as indicated, PT pore opening was initiated by infusion
of Ca2+ and monitored by recording the decrease in A540 due to mitochondrial swelling. (B, D and F) The degree of PT pore opening was compared by using the absorbance decreases attained at
the time indicated by the broken lines in (A, C and E) and replotted as percentage activity (black symbols). In parallel incubations, mitochondria were sedimented immediately after Ca2+ addition
and CyP-A activity in the supernatant was determined (white symbols).
values provides an unequivocal measure of CyP-D inhibition.
Changes in  ϕM were monitored from the uptake of TMRE,
a ﬂuorescent, lipophilic cation accumulated by mitochondria
according to the magnitude of the potential. Figure 5(A) shows
typical images of TMRE accumulated within the mitochondria
of these cells. Mitochondria of the CyP-D+ clone accumulated
considerably less TMRE than wild-type cells, but the difference
was negated by CsA, which promoted uptake by the CyP-D+
cells. Maximal restoration of TMRE uptake by CyP-D+ cells was
obtained with approx. 0.8 μMC s A( F i g u r e5 C ) ,2 . 4μMm t C s A
(Figure 5D) and 2 μM SMBz-CsA (results not shown). The same
concentrations did not affect TMRE uptake by wild-type cells
[Figure 5B; also conﬁrmed for SMBz-CsA (results not shown)].
It may be concluded that approx. 0.8 μMC s A ,2μM SMBz-
CsA and 2.4 μM mtCsA are sufﬁcient to inhibit CyP-D in B50
cells.
To investigate whether mtCsA inhibited CyP-D selectively, i.e.
without appreciable inhibition of CyP-A, we needed a marker
of CyP-A activity. Previously, we reported that nitroprusside-
induced caspase activation in B50 cells is largely prevented by
CsA and by antisense suppression of CyP-A. This indicates
that CsA inhibits caspase activation in this model by inhibiting
CyP-A [23]. Although the speciﬁc site of action of CyP-A is
unresolved, this system offers a measure of CyP-A activity.
Antisense treatment decreased CyP-A expression by >85%
without affecting CyP-D (Figure 5F), and antisense treatment,
CsA and SMBz-CsA all reduced nitroprusside-induced activation
of caspase-3 (Figure 5E). Unlike CsA and SMBz-CsA, however,
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Figure 5 mtCsA preferentially inhibits CyP-D, rather than CyP-A, in B50 neuronal cells
(A) Wild-type B50 cells (WT), or a CyP-D+ clone overexpressing CyP-D (CLONE) were incubated with 50 nM TMRE for 30min (panels 1 and 3) after which 1 μM CsA was added and the cells
incubated for a further 30min (panels 2 and 4). (B–D) Wild-type (WT) or CyP-D+ cells were incubated in the presence or absence of the indicated concentrations of CsA and mtCsA. TMRE uptake
was measured by whole cell ﬂuorescence determined at intervals. The results are the means+ −S.E.M. for four experiments. (E)C y P - D + cells pretreated with CyP-A antisense oligodeoxynucleotide
(AS; 42 h), 0.8μMC s A ,2μM SMBz-CsA or 2.4 μM mtCsA (for 10min) were incubated with or without 100μM nitroprusside (for 40min) and extracts were assayed for caspase-3. *P<0.05,
comparing test nitroprusside data with control (no addition) nitroprusside data over four experiments. (F) Immunoblots showing that CyP-D overexpression (CyP-D+) does not change CyP-A, and
that CyP-A knockdown (AS CyP-A) does not change CyP-D.
I/R and glutamate-induced injury in hippocampal neurons
I/R was mimicked by incubating hippocampal neurons under
OGD conditions for 30 min, after which glucose and oxygen
were restored. To estimate the time period of OGD needed
to remove oxygen sufﬁciently for impairment of mitochondrial
electron transport, we followed TMRE loss from mitochondria of
preloaded cells as an index of  ϕM dissipation. TMRE was lost
after approx. 5 min OGD, indicating respiratory inhibition at this
time(resultsnotshown).Attheoutsetofeachexperiment,agroup
ofhippocampalneuronswere distinguishedfromunderlyingglial
cells and the same neurons were imaged at intervals thereafter.
The susceptibility of neuronal cells (but not glial cells) to OGD-
induced necrosis increased with the number of days in culture,
and results were obtained after culture for 24–28 days.
Following OGD, approx. 60% of neurons became necrotic
within 90 min (Figure 6A), but mortality was approximately
halved in the presence of mtCsA. Maximal protection was given
with >0.8 μM mtCsA (Figure 6B). CsA was less protective
(Figure 6B). There was a relatively small protection with
0.1 μM CsA, but this was reversed at higher CsA concentrations,
suggesting the existence of secondary CsA targets outside
mitochondria that counteracted the protection. Thus restricting
the action of CsA to mitochondria using mtCsA improves its
protective capacity against cell necrosis brought about by a
period of OGD, indicating that CyP-D and the PT pore are major
contributors to this form of injury.
In vivo, a major component of I/R-induced neuronal injury is
believed to be initiated by prolonged exposure to extracellular
glutamate and overactivation of ionotropic glutamate receptors.
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Figure 6 Mitochondrial targeting enhances protection of hippocampal
neurons by CsA following transient oxygen and glucose deprivation
(A) Hippocampal neurons were preincubated under OGD for 30min, and then returned to
glucose-replete normoxia (OGD). The experiment was repeated with mtCsA included in both
anoxic and normoxic media (OGD+mtCsA). The lower curve is without an OGD step (No
ODG). Necrotic cells were quantiﬁed from nuclear staining with ethidium homodimer. (B) Cells
were incubated with CsA or mtCsA and necrosis determined after 30 min OGD and 90min
glucose-replete normoxia. Results are means+ −S.E.M. for ﬁve cell preparations with >20 cells
per preparation.
Toinvestigate PTpore involvementin glutamate toxicity,neurons
were exposed to added glutamate under normoxic conditions in
the presence of glucose. Following a short lag-period, this led
to progressive necrosis (Figure 7A). Surprisingly, the relative
protective capacities of CsA and mtCsA were now reversed with
respect to OGD. Whereas CsA yielded good protection, mtCsA
was ineffective (Figure 7B). In a further series of experiments
(Figure 8A), mtCsA did reduce necrosis to a small extent (24%,
but not signiﬁcant) but, again, CsA was far more effective
with 88% protection. Thus restricting the action of CsA to
mitochondria with mtCsA largely removes protection by CsA,
indicating that CsA attenuates glutamate toxicity by interacting
with extramitochondrial CyPs, rather than intramitochondrial
CyP-D.
As expected, glutamate-induced necrosis was prevented
by glutamate antagonists, i.e. by MK-801, an NMDA (N-
methyl-D-aspartate) receptor antagonist, and by NBQX, an
AMPA (amino-3-hydroxy-5-methyl-4-isoxazole proprionic acid)
receptor antagonist (Figure 8A). However, glutamate antagonists
had relatively little effect on OGD-induced necrosis (Figure
8B), indicating negligible contribution of glutamate toxicity
under this protocol (any glutamate released from the cells
during anoxia was presumably quickly diluted in the incubation
medium). Thus the involvement of extramitochondrial CyPs
in CsA protection correlates with glutamate toxicity, whereas
their involvement in CsA counterprotection correlates with
OGD-induced necrosis. To investigate whether these effects,
Figure 7 CsA, but not mtCsA, strongly reduces glutamate toxicity in
hippocampal neurons
(A) Hippocampal neurons were incubated in Locke’s medium with () and without ()1m M
glutamate at 37◦C and cell viability was determined from nuclear staining with ethidium
homodimer. Results from a single representative preparation. (B) Neurons were incubated in
Locke’s medium with CsA ()o rm t C s A( ). After 10min, 1 mM glutamate was added and
cell necrosis determined 3 hours later. Results are means+ −S.E.M. of ﬁve cell preparations with
>20 cells per preparation.
both protective (glutamate) and counterprotective (OGD), might
involve inhibition of calcineurin by the CsA–CyP-A complex,
we used FK506 (an immunosuppressant macrolide) which, as the
FK506–FKBP (FK506-binding protein) complex, also inhibits
calcineurin. As shown in Figure 8(B), FK506 partially reversed
mtCsA-protection against OGD-induced necrosis, indicating that
calcineurin inhibition is counterprotective. In contrast, FK506
partially prevented glutamate-induced necrosis. Thus calcineurin
appears to have opposing roles in OGD-induced and glutamate-
induced cell death.
Calcineurin dephosphorylates, and thereby activates, neuronal
NO synthase, and this activation is believed to contribute to
glutamate toxicity [27]. However, the NO synthase inhibitor L-
NAME did not yield signiﬁcant protection. Indeed, it is notable
that both L-NAME and FK506 were less effective than CsA (Fig-
ure 8A). To test whether the acute effectiveness of CsA against
glutamate toxicity reﬂected a dual action in inhibiting both
calcineurin and CyP-D (and the PT pore), we applied FK506 and
mtCsA together; however this was no more effective than FK506
alone.Thisconﬁrmsthattheinhibitionofglutamateexcitotoxicity
by CsA is not due to inhibition of CyP-D.
The greater effectiveness of CsA compared with mtCsA plus
FK506 in inhibiting glutamate-induced necrosis (Figure 8A)
suggests that CsA-mediated inhibition of extramitochondrial
CyPs (PPIase activity) may also be protective. This was further
investigatedusingSMBz-CsA,whichinhibitsCyPPPIaseactivity
(Figure1),butnotcalcineurinwhenincomplexwithCyP-A(Fig-
ure 3). Similar to CsA, SMBz-CsA permeates into mitochondria
and inhibits the PT pore (Figure 4E), but is not accumulated by
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Figure 8 Protection against glutamate-induced and OGD-induced necrosis
in hippocampal neurons
(A) Glutamate-induced necrosis. Hippocampal neurons were incubated in Locke’s medium
containingeithernoaddition(−),1μMCsA,1.3μMmtCsA,1μMFK506,250μM L-NAME,
1 μM FK506 and 1.3μM mtCsA (mtCsA+FK506), 50μM MK801 or 100μM NBQX. After
10min,1mMglutamatewasaddedandcellnecrosiswasdetermined3hlater .(B)OGD-induced
necrosis. Neurons were subjected to oxygen and glucose deprivation for 30min, and then
glucose-replete normoxia for 90min, before necrosis was quantiﬁed. Inhibitors were added to
both anoxic and normoxic media at concentrations as in (A). Results are means+ −S.E.M. of
ﬁve cell preparations with >20 cells per preparation. *P<0.05; **P<0.01 with respect to no
addition.
mitochondria (Figure 4F) and it enters cells where it inhibits
CyP-A (Figure 5E). As shown in Figure 9, SMBz-CsA was
more cytoprotective than mtCsA, consistent with some protection
due to inhibition of extramitochondrial CyPs. Figure 9 also
shows that SMBz-CsA was a better cytoprotectant than CsA
following OGD and that, unlike CsA (Figure 6), protection was
not reversed with an increased SMBz-CsA concentration. This
may reﬂect the lack of calcineurin inhibition by SMBz-CsA, as
calcineurin inhibition appears to be counterprotective in OGD-
induced necrosis (Figure 8B, mtCsA compared with mtCsA plus
FK506). However, SMBz-CsA yielded less cytoprotection than
mtCsA, suggesting that inhibition of extramitochondrial CyPs
mightalsobecounterprotectiveinOGD-inducednecrosis(Figure
9). This is consistent with the fact that FK506 does not fully
reverse cytoprotection by mtCsA (Figure 8B). In summary, the
involvement of CyPs and calcineurin appears to differ between
the two forms of injury; CyP-D inhibition is more protective after
OGD than after glutamate, whereas inhibition of calcineurin and
extramitochondrialCyP(s)ismoreprotectiveafterglutamatethan
after OGD (when these interventions actually reverse protection).
These differences point to different pathogenic mechanisms.
Figure 9 Cytoprotection by SMBz-CsA
Glutamate-induced and OGD-induced necrosis in hippocampal neurons was determined as
in Figure 8 in the presence of 0.3–2.0μM CsA, SMBz-CsA and mtCsA, as indicated. In the
absenceofCsAandderivatives,necrosiswas34+ −5%(glutamate)and64+ −6%(OGD).Results
are means+ −S.E.M. of ﬁve cell preparations with >20 cells per preparation. *P<0.05 for




and forming interactions with 15 amino acids [28]. The binding
region in CyPs is highly conserved. In particular, apart from a
single conservative substitution (lysine for arginine), the binding
residues in CyP-A are all present in CyP-D, and a high resolution
structureofCyP-DhasconﬁrmedthatthesameresiduesasinCyP-
A make contact with CsA [29]. Although differences in adjacent
aminoacidsmightofferpotentialforselectiveinhibition,theCsA-
bindingafﬁnitiesofCyP-DandCyP-Aareaboutthesame(Figure
1). It is therefore difﬁcult to envisage CyP-D selectivity based on
binding afﬁnities alone.
To address this problem, CsA was conjugated to the lipophilic
cation TPP
+ in order to allow electrophoretic accumulation
within mitochondria. The CyP-binding amino acids in CsA
have been identiﬁed as residues 9–11 and 1–3 [28]. However,
substitution at the sarcosine in position-3 does allow retention
of the tight binding to CyPs [30], and the same position was
utilized in the present study for conjugation to TPP
+.I nt h e
ternaryCyP–CsA–calcineurincomplex,positions3–7oftheCsA
ring form contacts with calcineurin [26,28]. As expected the
position-3 conjugates, SMBz-CsA and mtCsA, therefore were
unable to bind to calcineurin (Figure 3). The position-3 addition
also reduced the binding afﬁnity to CyPs (Figure 1). This
reduction was marginal for SMBz-CsA, presumably reﬂecting
steric factors, but was marked in the case of mtCsA. A possible
explanation lies in the fact that the predominant conformation
of free CsA is quite different from that bound to CyPs [28] and
modiﬁcations that stabilize the unbound conformations would
effectivelylowerthebindingafﬁnityforCyPs.Inaddition,mtCsA
would be more lipophilic than CsA itself given the nature of the
linking region. The TPP
+ moiety, however, would not increase
lipophilicity (the octanol/buffered saline partition coefﬁcient of
triphenylmethylphosphonium is 0.35 [31]). In this connection,
analyses of radiolabelled CsA binding to mitochondria reveal
that there are components besides CyP-D that bind CsA [32];
these components bind CsA far more weakly than CyP-D, but are
present in excess. For mtCsA, which bound with a 30-fold lower
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afﬁnity to CyP-D compared with CsA, the matrix free-mtCsA
concentration needed to block the PT will be 30-fold higher
than for CsA, and unspeciﬁc binding to other components will
be correspondingly greater. Thus the combination of decreased
CyP-D-binding afﬁnity, increased partitioning into membrane
phospholipids, and unspeciﬁc binding may explain why more
mtCsA than CsA was needed to inhibit the PT pore (Figures
4B and 4D). Nevertheless, mtCsA displayed a good selectivity
for intramitochondrial CyP-D over extramitochondrial CyP-A
when tested in a mixed in vitro system (Figure 4D) and in
intact B50 cells (Figure 5). The latter made use of the fact




M. Crompton, unpublished work], CyP-D and the PT pore do not
appear to be involved in this process [33]. Thus the fact that
mitochondrial targeting of CsA largely removes its capacity to
inhibit apoptosis in this system (Figure 5E) is consistent with
mitochondrial accumulation of the conjugate out of the cytosol.
CyPs have both positive and negative roles in cell viability;
CyP-D is linked to the PT, CyP-A (cytosol) participates in
the translocation of AIF (apoptosis inducing factor) to the
nucleus [34], in caspase activation [23] and in protection
against oxidative stress [35] and CyP-B (endoplasmic reticulum)
suppresses apoptosis associated with oxidative stress and altered
Ca
2+ metabolism [36]. In addition, the CyP-A–CsA complex
inhibits calcineurin, which dephosphorylates pro-apoptotic BAD
(Bcl-2/Bcl-XL-antagonist, causing cell death) [37] and the L-
type Ca
2+ channel [38] in neurons. The effects on calcineurin
are avoided with some CsA derivatives, e.g. NIM811 and Debio-
025 [39], as with SMBz-CsA (Figure 3), but these derivatives
remain general CyP inhibitors and their overall effects can be
difﬁcult to interpret. For example, SMBz-CsA protected against
both glutamate- and OGD-induced necrosis (Figure 9). At face
value, this could be taken to indicate similar roles of CyP-D and
the PT pore in the two cases. However, use of the CyP-D-speciﬁc
mtCsA reveals that this is not the case.
The extent to which the CyP-D-dependent PT pore is the root
cause of ischaemic cell death was addressed in neuronal cells,
where the issue appears complex. Many models of transient
ischaemiashowthatprotectionofhippocampalandotherneuronal
cellsbyCsAisequalledbyFK506,suggestingthatCsAinhibition
of calcineurin-mediated processes, rather than the PT, is critical
(reviewed in [39]). In contrast, other studies point to a primary
role of the PT [8,40,41]. Thus CsA inhibition of both calcineurin
and the PT may yield cytoprotection in different proportions




state (the phosphorylation potential) becomes compromised in
ischaemia as glycolysis and the tricarboxylic acid cycle are
inhibited due to lack of glucose and oxygen, leading to ‘energy
failure’.Inaddition,anduniquetoneuronaltissue,activetransport
systems for glutamate uptake in astrocytes and neurons (normally
responsible for termination of synaptic transmission) operate
in reverse during energy failure leading to high extracellular
glutamate and over-activation of neuronal glutamate receptors
[42]. Both types of insult produce qualitatively similar changes




generates ROS (reactive oxygen species) (reviewed in [43]).
Similarly, addition of high exogenous glutamate under aerobic
conditions causes excessive Ca
2+ inﬂux into the cell, depletion
of ATP and ADP, and oxidative stress [40,44]. Moreover, there
is evidence that glutamate toxicity requires mitochondrial Ca
2+
uptake and induces mitochondrial dysfunction ( ϕM dissipation)
[40,45], consistent with PT pore formation. Accordingly, it might
be expected that the PT pore would contribute similarly to
injury resulting from transient energy failure alone and from
glutamate toxicity. Surprisingly, however, comparisons of the
cytoprotective capacities of CsA and mtCsA reveal markedly
differing contributions of the PT pore in the two forms of
pathogenesis.
Although CsA-mediated inhibition of glutamate toxicity is
frequently ascribed to inhibition of CyP-D and prevention of the
PT, we obtained no indication for this, as the inhibition of
glutamate-induced necrosis by CsA was largely abolished by
mitochondrial targeting. This mirrors a previous report showing
thatgeneticablationofCyP-Dhadnoeffectonglutamatetoxicity
in hippocampal neurons [45]. It appears that the major site of




was protective (Figure 8A) and SMBz-CsA was less protective
than CsA (Figure 9). This may involve calcineurin-mediated
activation of neuronal NO synthase. Neuronal NO synthase
is a Ca




inﬂux [46]. Our results are consistent with this. However, as CsA
was a better inhibitor of glutamate-induced necrosis than either
FK506 (and hence calcineurin inhibition) or L-NAME (and hence
NO synthase inhibition), and the extra inhibition is not explained
by CyP-D inhibition, it appears that inhibition of extramitochon-
drial CyPs may also play a role in CsA-mediated protection
against glutamate-induced necrosis. Consistent with this, SMBz-
CsA was a better cytoprotectant than mtCsA (Figure 9).
In contrast, the major site of CsA-mediated protection against
OGD-induced necrosis appears to be mitochondrial. Thus




to transient OGD [4] and in perfused heart [7]. Secondary,
extramitochondrial targets of CsA presumably negate protection
gained by PT inhibition as the CsA concentration is increased.
These counterprotective targets may include calcineurin, as
mtCsA-mediated protection was decreased by FK506 (Figure
8B), and SMBz-CsA was a better cytoprotectant than CsA
(Figure 9). Other extramitochondrial counterprotective targets
cannot be ruled out, as mtCsA protection was only partially
reversed by FK506 (Figure 8B) and mtCsA was a better
cytoprotectant than SMBz-CsA (Figure 9). The augmented
protective capacity of CsA against OGD-induced necrosis
obtained by mitochondrial targeting cannot be explained by
increased inhibition of mitochondrial CyP-D, as CsA was
tested at concentrations (1 μM) sufﬁcient to inhibit CyP-
D completely (in B50 cells, 0.8 μM total CsA completely
reversed the PT activation by CyP-D overexpression; Figure
5C). Rather, enhanced protection by mtCsA must reﬂect the
relatively low mtCsA concentration outside mitochondria so
that non-mitochondrial, counterprotective effects of CsA are
minimized. Overall, enhanced protection by mtCsA indicates that
it protects against energy-failure-induced necrosis by inhibiting
mitochondrial CyP-D and supports the applicability of the PT
pore model of pathogenesis to this form of injury.
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In conclusion, we have developed a novel, mitochondrially
targeted CsA and shown that it selectively inhibits the
mitochondrial CyP-D-dependent PT pore compared with
extramitochondrial CyP-A in intact cells. Application of this
targeted CsA to hippocampal neurons exposes a marked
difference between the contribution of CyP-D to necrosis induced
by glutamate alone (a low contribution) and that arising simply
from energy failure (a high contribution). The latter protocol may
be representative of I/R injury to cells in general when glutamate
doesnotcontribute.Inthesecases,asselectivetargetingofCsAto
mitochondria produces better protection against transient OGD-
induced cell necrosis than CsA itself, the therapeutic potential of
CsA in limiting reperfusion injury, recently tested in pilot trials
[20], may be improved by mitochondrial targeting.
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